Lisdexamfetamine

From Wikipedia, the free encyclopedia

Lisdexamfetamine
Systematic (IUPAC) name
(S)-2,6-diamino-N-[(S)-1-phenylpropan-2-yl]hexanamide
Identifiers
CAS number 608137-32-2
ATC code  ?
PubChem  ?
Chemical data
Formula C15H25N3O 
Mol. mass 263.38
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Lisdexamfetamine (L-lysine-d-amphetamine), marketed under the name Vyvanse, is a prodrug indicated for treatment of attention-deficit hyperactivity disorder. It was developed by Shire and New River Pharmaceuticals and received approval from the U.S. Food and Drug Administration on February 23, 2007. Lisdexamfetamine is intended to provide an option of lower abuse potential, and the results of clinical trials seem to indicate that it is successful. 50mg of lisdexamfetamine contains 20mg of the stimulant d-amphetamine, the well-known abusable Schedule II option; because of its being bound to L-Lysine, this amphetamine is released and activated more slowly as the molecule is hydrolyzed in the digestive system. This delayed release produced less "likeability", less euphoric effect and a later peak time than amphetamine alone in clinical trials, suggesting that lisdexamfetamine may be appropriate for use with patients with history of stimulant abuse. Nevertheless, it is currently designated as Schedule II, the same as with conventional d-amphetamine.[1]

[edit] References and Notes

  1. ^ FDA packaging insert for Vyvanse
  1. ^ FDA packaging insert for Vyvanse